Cargando…
Cell-Based Therapies Formulations: Unintended components
Cell-based therapy is the fastest growing segment of regenerative medicine, a field that promises to cure diseases not treated by other small molecules or biological drugs. The use of living cells as the active medicinal ingredient present great opportunities to deliver treatment that can trigger th...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277633/ https://www.ncbi.nlm.nih.gov/pubmed/27233803 http://dx.doi.org/10.1208/s12248-016-9935-9 |
_version_ | 1783722115354066944 |
---|---|
author | Atouf, Fouad |
author_facet | Atouf, Fouad |
author_sort | Atouf, Fouad |
collection | PubMed |
description | Cell-based therapy is the fastest growing segment of regenerative medicine, a field that promises to cure diseases not treated by other small molecules or biological drugs. The use of living cells as the active medicinal ingredient present great opportunities to deliver treatment that can trigger the body’s own capacity to regenerate damaged or diseased tissue. Some of the challenges in controlling the quality of the finished cell-therapy product relate to the use of a variety of raw materials including excipients, process aids, and growth promotion factors. The quality of these materials is critical for ensuring the safety and quality of the finished therapeutic products. This review will discuss some of the challenges and opportunities associated with the qualification of excipients as well as that of the ancillary materials used in manufacturing. |
format | Online Article Text |
id | pubmed-8277633 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-82776332021-07-20 Cell-Based Therapies Formulations: Unintended components Atouf, Fouad AAPS J Mini-Review Cell-based therapy is the fastest growing segment of regenerative medicine, a field that promises to cure diseases not treated by other small molecules or biological drugs. The use of living cells as the active medicinal ingredient present great opportunities to deliver treatment that can trigger the body’s own capacity to regenerate damaged or diseased tissue. Some of the challenges in controlling the quality of the finished cell-therapy product relate to the use of a variety of raw materials including excipients, process aids, and growth promotion factors. The quality of these materials is critical for ensuring the safety and quality of the finished therapeutic products. This review will discuss some of the challenges and opportunities associated with the qualification of excipients as well as that of the ancillary materials used in manufacturing. Springer International Publishing 2016-05-27 /pmc/articles/PMC8277633/ /pubmed/27233803 http://dx.doi.org/10.1208/s12248-016-9935-9 Text en © The Authors 2016 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Mini-Review Atouf, Fouad Cell-Based Therapies Formulations: Unintended components |
title | Cell-Based Therapies Formulations: Unintended
components |
title_full | Cell-Based Therapies Formulations: Unintended
components |
title_fullStr | Cell-Based Therapies Formulations: Unintended
components |
title_full_unstemmed | Cell-Based Therapies Formulations: Unintended
components |
title_short | Cell-Based Therapies Formulations: Unintended
components |
title_sort | cell-based therapies formulations: unintended
components |
topic | Mini-Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277633/ https://www.ncbi.nlm.nih.gov/pubmed/27233803 http://dx.doi.org/10.1208/s12248-016-9935-9 |
work_keys_str_mv | AT atouffouad cellbasedtherapiesformulationsunintendedcomponents |